Literature DB >> 28882997

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.

Lena F Burbulla1,2, Pingping Song1, Joseph R Mazzulli1,2, Enrico Zampese3, Yvette C Wong1, Sohee Jeon1, David P Santos1, Judith Blanz1, Carolin D Obermaier4,5,6, Chelsee Strojny1, Jeffrey N Savas1, Evangelos Kiskinis1, Xiaoxi Zhuang7, Rejko Krüger4,6,8, D James Surmeier3, Dimitri Krainc9,2.   

Abstract

Mitochondrial and lysosomal dysfunction have been implicated in substantia nigra dopaminergic neurodegeneration in Parkinson's disease (PD), but how these pathways are linked in human neurons remains unclear. Here we studied dopaminergic neurons derived from patients with idiopathic and familial PD. We identified a time-dependent pathological cascade beginning with mitochondrial oxidant stress leading to oxidized dopamine accumulation and ultimately resulting in reduced glucocerebrosidase enzymatic activity, lysosomal dysfunction, and α-synuclein accumulation. This toxic cascade was observed in human, but not in mouse, PD neurons at least in part because of species-specific differences in dopamine metabolism. Increasing dopamine synthesis or α-synuclein amounts in mouse midbrain neurons recapitulated pathological phenotypes observed in human neurons. Thus, dopamine oxidation represents an important link between mitochondrial and lysosomal dysfunction in PD pathogenesis.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28882997      PMCID: PMC6021018          DOI: 10.1126/science.aam9080

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  24 in total

1.  Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Authors: 
Journal:  Mov Disord       Date:  2013-09-30       Impact factor: 10.338

Review 2.  Parkinson's disease.

Authors:  Lorraine V Kalia; Anthony E Lang
Journal:  Lancet       Date:  2015-04-19       Impact factor: 79.321

Review 3.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

4.  Calcineurin determines toxic versus beneficial responses to α-synuclein.

Authors:  Gabriela Caraveo; Pavan K Auluck; Luke Whitesell; Chee Yeun Chung; Valeriya Baru; Eugene V Mosharov; Xiaohui Yan; Manu Ben-Johny; Martin Soste; Paola Picotti; Hanna Kim; Kim A Caldwell; Guy A Caldwell; David Sulzer; David T Yue; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-13       Impact factor: 11.205

5.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

6.  DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology.

Authors:  Ricardo Taipa; Conceição Pereira; Inês Reis; Isabel Alonso; António Bastos-Lima; Manuel Melo-Pires; Marina Magalhães
Journal:  Brain       Date:  2016-04-16       Impact factor: 13.501

Review 7.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

8.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

9.  Robust pacemaking in substantia nigra dopaminergic neurons.

Authors:  Jaime N Guzman; Javier Sánchez-Padilla; C Savio Chan; D James Surmeier
Journal:  J Neurosci       Date:  2009-09-02       Impact factor: 6.167

10.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

Authors:  D Sulzer; J Bogulavsky; K E Larsen; G Behr; E Karatekin; M H Kleinman; N Turro; D Krantz; R H Edwards; L A Greene; L Zecca
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

View more
  211 in total

Review 1.  Neurobehavioral changes arising from early life dopamine signaling perturbations.

Authors:  Lorena B Areal; Randy D Blakely
Journal:  Neurochem Int       Date:  2020-04-20       Impact factor: 3.921

Review 2.  Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Maria Nguyen; Yvette C Wong; Daniel Ysselstein; Alex Severino; Dimitri Krainc
Journal:  Trends Neurosci       Date:  2018-11-30       Impact factor: 13.837

3.  LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.

Authors:  Maria Nguyen; Dimitri Krainc
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

4.  Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells.

Authors:  Alice Biosa; Federica De Lazzari; Anna Masato; Roberta Filograna; Nicoletta Plotegher; Mariano Beltramini; Luigi Bubacco; Marco Bisaglia
Journal:  Neurotox Res       Date:  2019-06-21       Impact factor: 3.911

5.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

6.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

7.  α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo.

Authors:  Yaqi Ding; Deqin Kong; Tong Zhou; Nai-di Yang; Chenqi Xin; Jiajia Xu; Qi Wang; Hang Zhang; Qiong Wu; Xiaomei Lu; Kahleong Lim; Bo Ma; Chengwu Zhang; Lin Li; Wei Huang
Journal:  Neuromolecular Med       Date:  2019-08-10       Impact factor: 3.843

Review 8.  The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

Authors:  Lena F Burbulla; Dimitri Krainc
Journal:  Neurobiol Dis       Date:  2019-07-25       Impact factor: 5.996

9.  Harnessing the Digital Exhaust: Incorporating wellness into the pharma model.

Authors:  Justin M Wright; Graham B Jones
Journal:  Digit Biomark       Date:  2018-04-11

Review 10.  Rhythms of life: circadian disruption and brain disorders across the lifespan.

Authors:  Ryan W Logan; Colleen A McClung
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.